home / stock / kaltf / kaltf news

KALTF News and Press, Kalytera Therapeutics From 04/08/21

Stock Information
Company Name: Kalytera Therapeutics
Stock Symbol: KALTF
Market: OTC
Website: kalytera.co
Menu
KALTF KALTF Quote KALTF Short KALTF News KALTF Articles KALTF Message Board
Get KALTF Alerts

News, Short Squeeze, Breakout and More Instantly...
KALTF - Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients

SAN FRANCISCO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that, based on significantly positive results in a controlled large animal model of sepsis...
KALTF - Kalytera Therapeutics Inc. Completes Name Change to Claritas Pharmaceuticals, Inc.

SAN FRANCISCO, April 02, 2021 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced that the Company has changed its name to Claritas Pharmaceuticals, Inc. The decision to rename the Company...

KALTF - Claritas Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107

SAN FRANCISCO and TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has completed GLP genotoxicity studies of R-107. Claritas i...

KALTF - Claritas Announces Addition of Perenlei Enkhbaatar, M.D., Ph.D., FAHA to the Company's Board of Directors

SAN FRANCISCO and TORONTO, March 26, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced the addition of Perenlei Enkhbaatar, MD, PhD, FAHA as an indep...
KALTF - Claritas Announces Appointment of Robert Farrell, J.D. as Chairman of the Company's Board of Directors

SAN FRANCISCO and TORONTO, March 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that Robert Farrell, J.D., the Company’s President and CEO h...

KALTF - Claritas Announces Completion of Canine Toxicology Studies

SAN FRANCISCO and TORONTO, March 17, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has completed toxicology studies of R-107 in canines. On Ma...

KALTF - Claritas Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107

SAN FRANCISCO and TORONTO, March 12, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has completed GLP toxicology studies of R-107 in rodents. C...
KALTF - Claritas Announces Formation of Nitric Oxide Scientific Advisory Board

SAN FRANCISCO and TORONTO, March 08, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced the formation of a Scientific Advisory Board ( “SAB”...

KALTF - Claritas (formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea, Ph.D. to the Company's Board of Directors

SAN FRANCISCO and TORONTO, March 05, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced the addition of Professor Salvatore Cuzzocrea, Ph.D. as an independent member of the Company’s boar...

KALTF - Claritas (formerly Kalytera Therapeutics) Announces Additional Program to Reduce the Rate and Spread of COVID-19 with Prophylactic R-107 Nasal Spray Designed to Provide Sustained Release of Nitric Oxide in the Nasal Cavities

SAN FRANCISCO and TORONTO, March 04, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has initiated a second development program with R-107, the ...
Previous 10 Next 10